Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$118.30
-0.2%
$114.84
$85.60
$121.83
$146.79B0.348.04 million shs4.46 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$62.79
+16.2%
$50.66
$18.33
$72.98
$14.19B2.2532.67 million shs54.49 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.39
-0.5%
$24.88
$20.92
$29.82
$138.69B0.5546.91 million shs47.58 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.23%+1.46%+3.43%+7.86%+39.31%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-1.33%-6.42%-2.46%+4.57%+164.11%
Pfizer Inc. stock logo
PFE
Pfizer
-0.77%-6.64%+2.57%-0.26%-15.66%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$118.30
-0.2%
$114.84
$85.60
$121.83
$146.79B0.348.04 million shs4.46 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$62.79
+16.2%
$50.66
$18.33
$72.98
$14.19B2.2532.67 million shs54.49 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.39
-0.5%
$24.88
$20.92
$29.82
$138.69B0.5546.91 million shs47.58 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.23%+1.46%+3.43%+7.86%+39.31%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-1.33%-6.42%-2.46%+4.57%+164.11%
Pfizer Inc. stock logo
PFE
Pfizer
-0.77%-6.64%+2.57%-0.26%-15.66%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.86
Moderate Buy$118.08-0.18% Downside
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
1.93
Reduce$38.92-38.02% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.37
Hold$28.3516.23% Upside

Current Analyst Ratings Breakdown

Latest PFE, HIMS, and GILD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
10/10/2025
Pfizer Inc. stock logo
PFE
Pfizer
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$33.00 ➝ $32.00
10/9/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$129.00 ➝ $135.00
10/8/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy (B)
10/8/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$98.00 ➝ $100.00
10/8/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$125.00 ➝ $135.00
10/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/3/2025
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$28.00 ➝ $30.00
10/1/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$28.00
9/27/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy (B)
9/27/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$28.75B5.10$6.87 per share17.21$15.44 per share7.66
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$1.48B9.61$0.40 per share155.41$2.16 per share29.07
Pfizer Inc. stock logo
PFE
Pfizer
$63.83B2.17$4.30 per share5.67$15.62 per share1.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$480M$5.0223.5714.590.8021.86%50.99%17.24%10/30/2025 (Estimated)
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$126.04M$0.8078.49120.753.749.63%26.26%13.06%11/3/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.8812.988.050.8216.84%21.42%9.12%11/4/2025 (Estimated)

Latest PFE, HIMS, and GILD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2025Q3 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.79N/AN/AN/A$16.94 billionN/A
11/3/2025Q3 2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.09N/AN/AN/A$578.99 millionN/A
10/30/2025Q3 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$2.16N/AN/AN/A$7.42 billionN/A
8/7/2025Q2 2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.96$2.01+$0.05$1.55$6.95 billion$7.08 billion
8/5/2025Q2 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.58$0.78+$0.20$0.51$13.43 billion$14.65 billion
8/4/2025Q2 2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.18$0.17-$0.01$0.17$550.06 million$544.83 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.162.67%N/A62.95%10 Years
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.05%N/A91.49%16 Years

Latest PFE, HIMS, and GILD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/9/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.82%11/7/202511/7/202512/1/2025
7/29/2025
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
quarterly$0.792.81%9/15/20259/15/20259/29/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.13
1.32
1.15
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
1.72
4.98
4.46
Pfizer Inc. stock logo
PFE
Pfizer
0.65
1.16
0.85

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.27%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
17.71%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,6001.24 billion1.24 billionOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
1,637226.02 million185.99 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable

Recent News About These Companies

TD Asset Management Inc Increases Holdings in Pfizer Inc. $PFE
MGO One Seven LLC Sells 34,062 Shares of Pfizer Inc. $PFE
Pfizer Seeks Expanded Use Approval For Breast Cancer Drug
NorthRock Partners LLC Buys 18,323 Shares of Pfizer Inc. $PFE
Cypress Capital Group Has $291,000 Position in Pfizer Inc. $PFE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Gilead Sciences stock logo

Gilead Sciences NASDAQ:GILD

$118.30 -0.18 (-0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$118.39 +0.09 (+0.08%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$62.79 +8.77 (+16.23%)
Closing price 03:59 PM Eastern
Extended Trading
$62.24 -0.54 (-0.87%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Pfizer stock logo

Pfizer NYSE:PFE

$24.39 -0.13 (-0.51%)
Closing price 03:59 PM Eastern
Extended Trading
$24.40 +0.01 (+0.02%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.